Clinical Trial Update: Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection [Phase 2]

View source ↗

Summary

Phase 2 maintenance-dose study of GEN-003 in subjects with genital herpes (HSV-2 infection) was terminated; results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genital Herpes
• Herpes Simplex Virus Type Infection

Drugs mentioned

• GEN-003

Snippet

Sponsor: Genocea Biosciences, Inc. | Conditions: Genital Herpes, HSV-2 Infection | Phase 2 | Status: TERMINATED | Results posted: 2019-02-19